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 Abstract 
Inducible heat shock protein (HSP)70 (HSP70-1A and HSP70-1B proteins) is a 
chaperone responsible for assisting proper protein folding. Following stress conditions, 
HSP70 is highly up-regulated to mediate cytoprotective functions. In addition, HSP70 is 
able to trigger innate and adaptive immune responses that promote the immune 
recognition of antigens and to act as a cytokine when it is released.   
The data in the literature are controversial with regard to expression studies in 
peripheral blood mononuclear cells (PBMCs). In the present study, we aimed to 
examine if alterations of HSP70-1A/B expression are involved in the autoimmune 
pathogenesis of multiple sclerosis (MS). We determined both mRNA and protein 
expression in PBMCs of MS patients and healthy donors (HDs). We found a baseline 
increased expression of the HSPA1A gene in PBMCs from MS patients compared with 
HDs. Gene expression findings were associated with an increased protein expression 
of HSP70-1A/B in T lymphocytes (CD4+ and CD8+) and monocytes from MS patients 
under basal conditions that may reflect the immunological activation occurring in MS 
patients. We also provided evidence that heat shock (HS) stimulus induced HSP70-
1A/B protein expression in HDs and MS patients, and that HS-induced HSP70-1A/B 
protein expression in monocytes correlated with the number of T2 lesions at baseline in 
MS patients. However, after lipopolysaccharide inflammatory stimulus monocytes from 
MS patients failed to induce HSP70-1A/B protein expression. Our data hint at altered 
immune responses in MS and may indicate either a state of chronic stress or increased 
vulnerability to physiological immune responses in MS patients.  
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Introduction 
Heat shock proteins (HSPs) are evolutionarily conserved chaperones that assist in the 
proper folding of newly synthesised proteins and are responsible for the quality control 
of misfolded proteins. Consequently, HSPs play an essential role in promoting cell 
survival following stress or harmful conditions such as heat shock, nutrient deprivation, 
irradiation, hypoxia, oxidative and toxic stresses, infection, and exposure to 
inflammatory cytokines. Under such stress conditions, inducible HSPs are highly up-
regulated as the result of a heat shock response to maintain cellular homeostasis and 
to facilitate cell survival functions (1-5).  
Among the HSPs, HSP70 is the most conserved and intensely studied family and 
includes the constitutively expressed HSC70 (HSP73) and the stress-inducible HSP70 
(HSP70-1A and HSP70-1B) proteins (6-8). HSP70 is located mainly in the cytosol. 
Adverse conditions trigger HSP70 expression, which then translocates to the nucleus 
and activates cytoprotective functions, acting as a chaperone and anti-apoptotic 
mediator. In addition to intracellular cytoprotective roles, HSP70 can be released 
actively via exosomes to the extracellular milieu, where it acts as a danger signal that 
induces immune responses. Furthermore, HSP70 can participate in the uptake and 
cross-presentation of antigens, and this role has been employed to improve tumor-
specific vaccination protocols (9-10). The above brief summary is far from complete, 
but indicates that HSP70 could be involved in chronic inflammatory and autoimmune 
conditions at multiple levels and by several different mechanisms.  
MS is considered a prototypic T cell-mediated autoimmune disease that is 
characterised by inflammation, and various degrees of demyelination, damage of 
axons and neurons and glial scarring in the central nervous system (CNS). The 
currently approved therapies of MS are all immunomodulatory or immunosuppressive, 
and neuroprotective approaches are being examined, but not yet available to patients. 
In CNS lesions in both MS patients and animals with experimental autoimmune 
encephalomyelitis (EAE), the prototypic animal model for MS, an up-regulation of 
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HSP70 expression has been observed and interpreted as activation of endogenous 
neuroprotective mechanisms (11-13). In contrast, Cwiklinska and co-workers (2003) 
detected HSP70–myelin basic protein (MBP) and HSP70–proteolipid protein (PLP) 
complexes in the CNS lesions of MS patients. Paradoxically, these MBP/PLP–HSP70 
complexes are highly immunogenic and are able to induce specific T-cell responses in 
animals with EAE (13-15).  
The genes coding for HSP70 (HSPA1A and HSPA1B) are located on chromosome 6 
(6p21.3) within the HLA region. Gene expression studies using microarrays have 
reported a down-regulation of HSPA1A expression in peripheral blood mononuclear 
cells (PBMCs) of MS patients compared to healthy donors (HDs) (16-19). Although 
histopathological studies have demonstrated an up-regulation of HSP70 in MS and 
EAE lesions, protein analyses of HSP70 expression in PBMCs did not reveal 
differences between MS patients and HDs (20). Despite the absence of differences in 
HSP70 protein expression in freshly isolated PBMCs, an increased induction of HSP70 
expression was observed in PBMCs of MS patients following an inflammatory or heat 
shock stimulus (20). The above data from previous studies as well as the known 
functions of HSP70 indicate that HSP70 itself and/or other family members of this 
fundamental cytoprotective pathway may be involved in the autoimmune pathogenesis 
of MS.  
Based on the above in part controversial observations, we aimed to investigate the 
potential role of HSP70 in MS pathogenesis by determining its gene and protein 
expression under different experimental conditions in a well-characterized cohort of 
relapse-onset MS patients and age- and gender-matched HDs.  
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Methods 
Patients  
Patients with clinically isolated syndromes (CIS) and untreated relapsing-remitting MS 
(RRMS) patients were included in this study. No patient had clinical exacerbations or 
had received corticosteroid treatment during the month prior to blood sample collection. 
An age- and gender-matched control group of HDs was also included. All patients and 
HDs gave their informed consent, and this study was approved by the local ethics 
committee. Demographic and baseline clinical characteristics of the MS patients and 
HDs included in the study are shown in Table 1. 
 
Sample collection  
Blood samples from MS patients and HDs were collected by standard venipuncture in 
sodium citrate tubes, and PBMCs were isolated by Ficoll-Isopaque density gradient 
centrifugation (Gibco BRL, Life Technologies LTD, UK) according to standard 
procedures. Isolated PBMCs were re-suspended in RPMI 1640 culture medium 
supplemented with 10% heat-inactivated foetal bovine serum (FBS), 2 mM glutamine, 
25 mM HEPES, 50 U/ml of penicillin, and 50 mg/ml of streptomycin, all obtained from 
Gibco BRL (Paisley, UK). Aliquots of PBMCs from a subgroup of MS patients and HDs 
were cryopreserved and stored in liquid nitrogen.  
 
HSP70 gene expression  
HSPA1A gene expression was analysed in fresh PBMCs (30 MS patients and 30 HDs) 
and in a subgroup of cryopreserved PBMC samples (9 MS patients and 10 HDs).  
Total RNA was obtained from both fresh and frozen PBMCs using an RNeasy Mini Kit 
(Qiagen, Germany). One microgram of RNA was retrotranscribed into cDNA using an 
Omniscript RT kit (Qiagen), and the gene expression levels of HSPA1A were assessed 
by real-time PCR relative quantification using Taqman expression assays (Applied 
Biosystems, CA, USA). PGK1 (phosphoglycerate-kinase 1; Applied Biosystems) was 
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used as an endogenous control. To select the appropriate endogenous control for data 
normalisation, 11 endogenous genes were previously tested using the Taqman human 
endogenous control plate (Applied Biosystems) in four PBMC samples from both MS 
patients and HDs. Real-time PCR was performed in an ABI Prism 7000 thermal cycler 
(Applied Biosystems) according to manufacturer’s instructions. The threshold cycle (CT) 
value for each reaction was used to calculate the relative level of gene expression for 
each sample using the 2-∆∆CT method (21). Samples were tested in triplicate.  
 
HSP70 protein expression  
The expression of intracellular HSP70-1A/B protein was assessed in CD4+ (CD3+CD8-
) and CD8+ (CD3+CD8+) T lymphocytes and monocytes (CD14+) by flow cytometry 
from non-stimulated PBMCs or from PBMCs stimulated by either heat shock (HS) or an 
inflammatory challenge (20). In brief, for the HS stimulus PBMCs were incubated at 
40°C overnight in a water bath followed by a 30-min recovery period at 37°C. The 
inflammatory stress was induced incubating PBMCs in the presence of 5 µg/ml 
lipopolysaccharide (LPS) (Sigma Aldrich, Saint Louis, MI) for 24 h in humidified 
atmosphere at 5% CO2 and 37ºC. Following stress stimuli, PBMCs were washed 
with phosphate-buffered saline (PBS) and incubated with a saturating amount of 
PerCP-conjugated anti-human CD3 (Becton Dickinson (BD) Pharmingen, San Diego, 
CA), FITC-conjugated anti-human CD8 (BD Pharmingen), and APC-conjugated anti-
human CD14 (BD Pharmingen) or the corresponding isotype controls (BD Pharmingen) 
for 25 min at room temperature. Then, the cells were washed with PBS and fixed and 
permeabilised using two different commercial intracellular staining protocols following 
the manufacturer’s instructions to quantify the cytoplasmic (Dako IntraStain, Fixation 
and Permeabilization kit; Dako, Denmark) and total (cytoplasmic plus nuclear) (BD 
Cytofix/Cytoperm; BD Bioscience) HSP70-1A/B protein expression. During the 
permeabilisation process, the cells were incubated with a PE-conjugated monoclonal 
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antibody against HSP70-1A/-1B (clone C92F3A-5, reference SPA-810PE, Stressgen, 
Assay Designs Inc., MI), or an isotype control antibody (IgG1-PE, BD Pharmingen).  
Data acquisition was performed on a FACSCantoTM flow cytometer and analysed with 
DIVA software (BD, Mountain View, CA). The mean fluorescence intensity (MFI) and 
percentage of HSP70-1A/B positive cells were calculated by subtracting the isotype 
control signal from the HSP70-1A/B specific signal.  
 
Statistical analysis 
Data are shown as mean values (standard deviation) unless otherwise stated. 
Statistical analysis was performed with SPSS 17.0 software (SPSS Inc., Chicago, IL) 
and Prism software (GraphPad version 5.1 software Inc., San Diego, CA) both for MS-
Windows. Parametric and nonparametric tests were used depending on the normality 
conditions. To compare data from two groups, Wilcoxon, Mann-Whitney-U, or t-tests 
were applied. When more than two groups were compared, a Friedman test along with 
Dunn’s post-hoc test was applied. Spearman correlations or generalized linear models 
were used to determine association between HSP70 expression and clinical or 
demographic variables of MS patients and HDs. Differences were considered 
statistically significant when p<0.05.  
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Results 
 
HSP70 gene expression is up-regulated in the PBMCs of MS patients  
We first investigated differences in HSPA1A gene expression by means of real-time 
PCR in fresh PBMCs from 30 MS patients and 30 HDs. As shown in Figure 1A, 
HSPA1A gene expression was increased 2.5-fold in PBMCs of MS patients compared 
to HDs (p=0.038). No associations of HSPA1A expression with either demographic or 
clinical variables of MS patients or HDs were found. 
To evaluate whether sample cryopreservation could modify HSP70 gene expression, 
HSPA1A mRNA expression levels were also determined in a subgroup of previously 
frozen/thawed PBMCs from 9 MS patients and 10 HDs. As depicted in Figure 1B, 
HSPA1A expression did not significantly differ between fresh and cryopreserved 
PBMCs from MS patients or HDs.  
 
Total HSP70-1A/B expression is increased in T lymphocytes and monocytes from MS 
patients  
We next examined HSP70-1A/B protein expression in CD4+ (CD3+CD8-) and CD8+ 
(CD3+CD8+) T lymphocytes and in monocytes (CD14+) from non-stimulated PBMCs 
of 32 MS patients and 30 age- and gender-matched HDs. Flow cytometry analysis 
showed no differences in the cytoplasmic MFI expression between MS patients and 
HDs (Fig. 2A). Similarly, the percentage of HSP70-1A/B positive cells was comparable 
between groups (data not shown).  
Because HSP70 translocates to the nucleus following stress conditions (22), we also 
analysed the total (cytoplasmic plus nuclear) cellular expression of HSP70-1A/B in a 
subgroup of 14 MS patients and 14 HDs. Interestingly, the PBMCs from MS patients 
exhibited a significant increase in total HSP70-1A/B protein expression compared to 
HDs in all cell types studied (for CD4, p=0.030; for CD8, p=0.007; for CD14, p=0.003) 
(Fig. 2B).  
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Neither HSP70-1A/B T cell nor monocyte expression was associated with baseline 
clinical or demographic variables of MS patients or HDs. 
 
Induction of HSP70-1A/B protein expression following HS or inflammatory stress 
To study the induction of HSP70-1A/B protein expression after stress stimulus, PBMCs 
from 14 MS patients and 14 HDs were challenged with a thermal (HS) or an 
inflammatory (LPS) stimulus, and both the cytoplasmic and total HSP70-1A/B 
expression levels were analysed in T lymphocytes and in monocytes. As shown in Fig. 
3, HS stress induced a total HSP70-1A/B expression in both T lymphocytes and 
monocytes in HDs (for CD4, p<0.001; for CD8, p=0.013; for CD14, p=0.003). HS also 
induced HSP70-1A/B expression in PBMCs from MS patients, and differences reached 
statistical significance for CD8+ T cells (p=0.021) and monocytes (p=0.001) from MS 
patients but not in CD4+ T cells (Fig. 3A). In addition, we found a positive correlation 
between total expression of HS-induced HSP70-1A/B protein in monocytes and the 
number of T2 lesions at baseline in MS patients (r=0.61; p=0.034). Interestingly, 
monocyte activation by LPS stimulation caused an increase in total HSP70-1A/B 
protein expression in HDs (p<0.001) but not in MS patients (Fig. 3B). No differences 
were observed when cytoplasmic HSP70-1A/B expression was analysed after either 
HS or LPS stimulus (data not shown). 
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Discussion and conclusions 
Traditionally, HSP70 has been considered to be involved in homeostatic functions and 
cytoprotection because it participates in proper protein folding, avoidance of folding 
mistakes, and hence in preventing protein aggregation (23-25). In addition, it has also 
been reported that HSP70 blocks multiple steps of the cellular apoptosis pathway (26-
29). Its close location to the MHC class II region, which remains the genomic region 
most consistently associated with an increased genetic risk for MS (30), suggested that 
HSP70 may be implicated in the altered immune response that takes place in the 
disease. Histopathological studies in MS patients have shown an up-regulation in 
HSP70 expression within CNS lesions (11-12, 31), findings that were interpreted as a 
protective response of local cells to the inflammatory environment (32). Studies in 
peripheral blood cells, however, have revealed a lower expression of HSPA1A, one of 
the inducible genes for HSP70, in MS patients compared with HDs (14-16).  
During recent years it has become clear that HSP70 serves a multitude of other 
functions than cytoprotection and could also be involved in autoantigen presentation of 
MBP/PLP–HSP70 complexes in MS patients (14) as well as more generally in eliciting 
innate and adaptive immune responses, which has recently been reviewed (33). 
Based on the above previous studies on HSPA1A gene expression, the data from 
protein expression in CNS tissue in MS and EAE, and the broader understanding of the 
roles of HSP70 in physiological and also pathological contexts (3-5, 34-35), we aimed 
here at re-addressing the question of HSPA1A expression in peripheral blood immune 
cells at the mRNA level by real-time PCR and also regarding protein expression by flow 
cytometry.  
Contrary to previous studies (14-16), HSPA1A expression was found to be up-
regulated in PBMCs from MS patients compared to HDs. When investigating the 
discrepancies across studies, it should be taken into account that in previous studies 
HSPA1A expression was determined with the microarray technology, and single gene 
validation of HSPA1A findings with more sensitive techniques, such as real-time PCR, 
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was lacking in all cases. Differences between studies were not related to the sample 
storage conditions, as in the present study HSPA1A expression was comparable 
between fresh cells and cryopreserved samples. Other factors that could have 
contributed to the discrepancies may be related to the clinical characteristics of MS 
patients: i) In the present study patients never received immunomodulatory or 
immunosuppressant treatment, whereas in previous studies patients with a washout 
period of 1-2 months between treatment and sample collection were considered eligible 
for gene expression profiling; ii) In the present study, PBMCs were collected from MS 
patients with active disease activity that fulfilled the criteria for immunomodulatory 
treatment. In this regard, differences in the activation status of PBMCs may also 
explain the differences observed across studies.   
As a next step, we analysed whether the up-regulation in HSPA1A gene expression 
also correlated with the protein expression levels. Cytoplasmic HSP70-1A/B protein 
expression levels were similar between MS patients and HDs. However, because 
HSP70 translocates to the nucleus following stress (22), we also determined the total 
(cytoplasmic plus nuclear) HSP70-1A/B protein expression. In line with the HSPA1A 
gene expression data, total HSP70-1A/B protein expression levels were significantly 
increased in T lymphocytes and monocytes from MS patients compared with HDs.  
Although MS etiopathogenesis is not yet fully understood, multiple lines of evidence 
support that CD4+ T cells, but also other cell types including CD8+ T lymphocytes and 
monocytes play important roles in the pathogenesis of MS (36). In this regard, 
increased cellular levels of total HSP70-1A/B protein in PBMCs may be the result of 
stress associated with the immune cell activation that occurs in MS (reviewed in (36-
37)). Cwiklinska and co-workers (2010) did not find differences in basal HSP70 protein 
expression in PBMCs from MS patients and HDs using a commercial ELISA kit. 
However, these authors reported an aberrant induction of HSP70 protein expression in 
PBMCs of MS patients following an inflammatory or heat stress (20). Using a similar 
protocol, we assessed protein induction of total HSP70-1A/B in T lymphocytes and 
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monocytes following HS and LPS stresses. The HS stimulus induced a significant 
increase in HSP70-1A/B protein expression in CD4+ T lymphocytes from HDs, that 
reached similar levels to those of non-stimulated CD4+ T cells from MS patients. 
However, in MS patients the induction of HSP70-1A/B expression showed by CD4+ T 
lymphocytes following HS stimulus was only moderate compared with that of HDs. 
These data seem to indicate that HSP70-1A/B is chronically induced in CD4+ T cells 
from MS patients and, as a result, HS stimulus failed to trigger a significant HSP70-
1A/B induction. Interestingly, we also found that the levels of total HSP70-1A/B protein 
expression by heat-shocked monocytes correlated with the number of T2 lesions at 
baseline. This could be accounted by the fact that monocytes/macrophages are part of 
the inflammatory cuffs found in the CNS of MS patients and the T2-weighted MRI is 
commonly applied to quantify the accumulated MS lesion load. Furthermore, it has 
described that human HSPs might promote autoimmunity by peptidomimetic 
mechanism due to their similarity with bacteria HSP paralogs (38).   
We also explore differences in HSP70-1A/B expression in monocytes stimulated with 
LPS. This stimulation primarily activates monocytes and consequently triggers HSP70-
1A/B expression in HDs and MS patients (20, 39-40). We found that monocytes from 
MS patients also exhibited reduced response to the inflammatory stimulus, since 
HSP70-1A/B up-regulation following LPS stimulation was restricted to the control 
population. The reasons behind this differential response to LPS stimulation in terms of 
HSP70-1A/B induction are unknown. However, it is tempting to speculate that the 
higher baseline HSP70-1A/B expression levels in monocytes from MS patients 
rendered the cells unresponsive to subsequent HSP70-1A/B-inducing stimuli. Other 
factors such a lower expression of TLR4, the LPS receptor, in monocytes from MS 
patients could also have contributed to these differential findings (41).  
In summary, we found a baseline increased expression of HSPA1A gene in PBMCs 
from MS patients compared with HDs. Gene expression findings were associated with 
an increased protein expression of HSP70-1A/B in T lymphocytes (CD4+ and CD8+) 
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and monocytes from MS patients under basal conditions that may reflect the 
immunological activation that occurs in MS patients. We also provided evidence that 
after a stress stimulus CD4+ T lymphocytes as well as monocytes from MS patients 
showed reduced induction of HSP70-1A/B protein expression. This points out that 
immune response is altered in MS and it may indicate a state of chronic stress in MS 
patients. These data suggest that strategies for reducing or inhibiting HSP70-1A/B 
expression may be beneficial for MS patients, and, in support of this possibility, it has 
been reported that HSP70-deficient mice are resistant to EAE (42). However, the side 
effects associated with the essential cytoprotective functions of HSP70-1A/B should be 
taken into account.  
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Figure Legends 
Figure 1. HSP70 gene expression is increased in MS patients. (A) HSP70 
(HSPA1A) relative gene expression was determined in total RNA from fresh PBMCs 
using real-time PCR, and PGK1 gene expression was used as an endogenous control. 
The results were normalised to the gene expression of HSP70 in HDs. MS patients 
showed 2.5-fold greater HSPA1A mRNA expression than HDs (N=30 in each group, 
p=0.038). (B) In a subgroup of MS patients and HDs, HSPA1A relative gene 
expression was also determined following PBMC cryopreservation. No alterations in 
HSPA1A expression were detected in cryopreserved PBMCs from either MS or HD 
(N=9 and N=10, respectively). Error bars represent the standard error of the mean 
(SEM). 
 
Figure 2. Total HSP70 protein expression is up-regulated in non-stimulated T 
lymphocytes and monocytes from MS patients.  Cytoplasmic (A) and total (B) 
HSP70-1A/B protein expression was studied in CD4+ and CD8+ T lymphocytes and 
monocytes under baseline conditions. Although no differences were found in 
cytoplasmic HSP70-1A/B protein expression between groups (N= 30 HD and N= 32 
MS patients), all cell types from MS patients showed increased total (cytoplasmic plus 
nuclear) HSP70-1A/B protein levels compared to HDs (N=14 in each group). Error bars 
represent SEM. 
 
Figure 3. Induction of HSP70-1A/B protein expression following HS or LPS 
stimulus. Comparison of total HSP70-1A/B protein expression at baseline conditions 
and following HS in CD4+ and CD8+ T lymphocytes and in monocytes (A) or following 
LPS stimulus in monocytes (B) from MS patients and HDs (N=14 in each group). Error 
bars represent SEM.  
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